From here is the main content.

Corporate Information

Corporate History

Year Nihon Pharmaceutical Co., Ltd Daigo Nutritive Chemicals, Ltd.
1921 Established a company in Chibune-cho, Nishinari-gun, Osaka for manufacturing of Polytamin, an amino acid preparation for hematopoiesis and nutritional fortification
Started manufacturing of the amino acid preparation Polytamin
1925   Signed an exclusive distribution agreement with Takeda Chobei Shoten
1939 Founded in Chofu, Omori-ku, Tokyo, for the manufacturing and sale of pharmaceutical products  
1946 Established a company in Ginza, Kyobashi-ku, Tokyo (which continues to exist to date)  
1949   Launched the amino acid preparation Polytamin for Injection
1950 Signed an exclusive distribution agreement with Takeda Pharmaceutical Co., Ltd. to sell pharmaceutical products  
1956 Launched "γ-Globulin," a human normal immunoglobulin product  
1970 Launched "Albumin," a human serum albumin product  
1974   Launched "Intrafat," an intravenous fat emulsion
1975 Launched "Glovenin," a freeze-dried, pepsin-treated, human normal immuno-globulin product  
1976   The marketing authorization of "Osvan" (disinfectant) was transferred from Takeda Pharmaceutical Co., Ltd.
1985 Moved the head office to Higashi-Kanda, Chiyoda-ku, Tokyo  
Launched "Glovenin-I," a freeze-dried, polyethylene glycol-treated, human normal immunoglobulin product  
1987   Started the contract manufacturing of Alinamin V for Takeda Pharmaceutical Co., Ltd.
October 1987 Nihon Pharmaceutical Co., Ltd. and Daigo Nutritive Chemicals, Ltd. merged (company name: Nihon Pharmaceutical Co., Ltd.)
December 1990 Launched "Mac-Amin," an amino acid/glycerin/electrolyte solution for injection
April 1992 Launched "Mineralin," a trace-element preparation for hyperalimentation
September 1997 Launched "Kenketsu Nonthron," a freeze-dried, concentrated human antithrombin III
June 1999 Kenketsu Glovenin-I was approved for the additional indication of "CIDP (chronic inflammatory demyelinating polyneuropathy)"
October 2008 Kenketsu Glovenin-I was approved for the additional indication of "pemphigus"
January 2011 Launched "MINCLEA Spraying Solution 0.8% for Endoscopy," a gastric peristalsis inhibitor
February 2013 MINCLEA Spraying Solution 0.8% for Endoscopy was approved for the additional indication of "the inhibition of gastric peristalsis during upper gastrointestinal endoscopic treatment"
July 2014 Kenketsu Glovenin-I for I.V. Injection was approved for the additional indications of "Stevens-Johnson syndrome and toxic epidermal necrolysis"
August 2016 Moved the head office to Akashi-cho, Chuo-ku, Tokyo (to the present day)